Open access · CC-BY
via OpenAlex
Glycated albumin: An old yet new biomarker in people with diabetes and the potential for novel applications
Journal of Diabetes Investigation · 2026
Abstract
Glycated albumin (GA), the product of nonenzymatic glycation of serum albumin, reflects the mean glucose levels over the preceding approximately 2 weeks, bridging the gap between daily self-monitoring of blood glucose and the roughly 3-month window covered by glycated hemoglobin (HbA1c) measurement. First quantified in the early 1980s, GA was long overshadowed by HbA1c, but at present, interest has revived for two reasons. First, HbA1c assessment proves unreliable when the erythrocyte lifespan or hemoglobin glycation is perturbed, as in patients with renal failure, hemolytic anemia, hemoglobin variants, and iron deficiency. Second, continuous glucose monitoring has drawn attention to postprandial excursions and shortterm glucose variability that are not captured by HbA1c. This review revisits GA's biology, measurement, standardization, clinical utility, limitations, and evidence linking it to diabetic complications. Because it responds within 2 weeks to treatment and is markedly influenced by postprandial glucose excursions, GA supports early monitoring of therapy, and its ratio to HbA1c serves as an index of postprandial glycemia and insulin secretion. However, it must also be recognized that conditions that alter albumin turnover change GA levels independently of blood glucose levels. The prognostic value of GA is strongest in patients on maintenance hemodialysis, although recent studies in various cohorts and a meta-analysis have expanded situations in which GA measurement is of prognostic value. New measurement approaches, including finger-prick sampling, weekly home measurement, and noninvasive saliva and tear assays, point toward a renewed role for GA measurement in everyday glucose monitoring in individuals with diabetes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/jdi.70447
- Canonical
- link ↗
- Fetched
- 2026-11-05 MST
Cite this
APA
Aihara, M., & Kubota, N. (2026). Glycated albumin: An old yet new biomarker in people with diabetes and the potential for novel applications. <em>Journal of Diabetes Investigation</em>. https://doi.org/10.1111/jdi.70447
Vancouver
Aihara M, Kubota N. Glycated albumin: An old yet new biomarker in people with diabetes and the potential for novel applications. Journal of Diabetes Investigation. 2026. doi:10.1111/jdi.70447.
BibTeX
@article{masakazu2026Glycat,
title = {Glycated albumin: An old yet new biomarker in people with diabetes and the potential for novel applications},
author = {Masakazu Aihara and Naoto Kubota},
journal = {Journal of Diabetes Investigation},
year = {2026},
doi = {10.1111/jdi.70447},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
VA Office of Research and Development 2010
Open access · US-GOV
Does Variation in Mean Red Cell Age Impact HbA1C Interpretation?
Frontiers in Pharmacology 2023
Open access · CC-BY
Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial
Endocrine Journal 2010
Open access · OA
Clinical impact of glycated albumin as another glycemic control marker
University of Cincinnati 2015
Open access · US-GOV
Measurement of Exhaled Lower Respiratory Carbon Monoxide and Correlation With Previous Measures of Red Cell Lifespan
Novo Nordisk A/S 2007
Open access · US-GOV
The Effect of Insulin Detemir on Glucose Control in Ageing Subjects With Type 2 Diabetes.
Current Diabetes Reports 2016
Open access · CC-BY